Asco

Pfizer Shares Updated Lung Cancer Bispecifics Data at ASCO

At the ASCO Annual Meeting, updated Phase 2 data for Pfizer's bispecific antibody PF-08634404 demonstrated activity as monotherapy in first-line PD-L1-expressing non-small cell lung cancer.